Clinical Trial Update: A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing long-acting injectable risperidone with placebo in schizophrenia reports effectiveness and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psychotic Disorders
• Schizophrenia

Drugs mentioned

• Risperdal Consta (risperidone long-acting injectable)

Snippet

Sponsor: Janssen, LP | Conditions: Schizophrenia, Psychotic Disorders | Phase 3 | Status: COMPLETED